CS
ATYR

Credit Suisse’s aTyr Pharma ATYR Stock Holding History

Credit Suisse’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-857
Closed -$33K – 4286
2016
Q2 		$33K Buy
+857
New +$39.8K ﹤0.01% 4172

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Credit Suisse's ATYR Position: Q3 2016 in Review

Credit Suisse sold out of aTyr Pharma (ATYR) in Q3 2016, closing a stake of 857 shares — an estimated $33K sold.

Credit Suisse first reported a position in ATYR in Q2 2016 and held it in 1 quarter. The position peaked at $33K in Q2 2016. 43 funds tracked by Wall St. Rank hold ATYR as of Q3 2016.

  • Credit Suisse reported no remaining aTyr Pharma position as of Q3 2016 after selling out during the quarter.
  • Credit Suisse sold 857 aTyr Pharma shares in Q3 2016, an estimated $33K.
  • Credit Suisse first reported a position in aTyr Pharma in Q2 2016 and held it in 1 quarter.
  • Credit Suisse's aTyr Pharma position peaked at $33K in Q2 2016.
  • 43 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2016.

Based on Credit Suisse's 13F filing for Q3 2016, filed 15 Nov 2016.